Drug Screening in Scn1a Zebrafish Mutant Identifies Clemizole as a Potential Dravet Syndrome Treatment

Nature Communications - United Kingdom
doi 10.1038/ncomms3410
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Serotonergic Modulation as Effective Treatment for Dravet Syndrome in a Zebrafish Mutant Model

ACS Chemical Neuroscience
BiochemistryMedicinePhysiologyCell BiologyCognitive Neuroscience
2016English

Large-Scale Phenotype-Based Antiepileptic Drug Screening in a Zebrafish Model of Dravet Syndrome

eNeuro
MedicineNeuroscience
2015English

Analysis of SCN1A Mutation and Parental Origin in Patients With Dravet Syndrome

Journal of Human Genetics
Genetics
2010English

Clinical and Genetic Factors Predicting Dravet Syndrome in Infants With SCN1A Mutations

Neurology
Neurology
2017English

Preclinical Animal Models for Dravet Syndrome: Seizure Phenotypes, Comorbidities and Drug Screening

Frontiers in Pharmacology
Pharmacology
2018English

Pharmacological Analysis of the Anti-Epileptic Mechanisms of Fenfluramine in Scn1a Mutant Zebrafish

Frontiers in Pharmacology
Pharmacology
2017English

Expecting the Unexpected: Lack of in Vivo Network Defects in an Scn1a Model of Dravet Syndrome

Epilepsy Currents
Neurology
2016English

Dravet Syndrome: Patients With Co-Morbid SCN1A Gene Mutations and Mitochondrial Electron Transport Chain Defects

Seizure : the journal of the British Epilepsy Association
MedicineNeurology
2012English

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

New England Journal of Medicine
Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy